On August 27th, st Tiansheng closed at 4.94 yuan, with a decrease of 0.20%, turnover rate of 0.59% and total market value of 1.57 1 100 million yuan. In the first half of this year, st Tiansheng completed a major asset restructuring and sold 565,438+0% equity of Chongqing Changsheng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Chongqing Pharmaceutical Holdings (000950). The transfer was completed on April 29, and ST Tiansheng retained 49% equity. Although the sale directly leads to the narrowing of the merger scope and the decline of operating income, it is conducive to increasing the liquidity needed for the company's development, stabilizing the company's business market share in Chongqing, and realizing the complementary advantages of both parties and the synergy of pharmaceutical circulation business. After divestiture, ST Tiansheng concentrated its resources on pharmaceutical manufacturing.
On the one hand, we will gradually adjust the development strategy and business structure, devote ourselves to the shift growth of the pharmaceutical industry, continue to enlarge and strengthen the market of oral solid preparations and small-volume injections, gradually increase the proportion of the output value of the pharmaceutical industry, and enhance the market competitiveness of its own varieties; At the same time, continue to strengthen the construction of marketing team, increase the market development and promotion of leading products and products with market potential, and seize market share.
During the reporting period, the company's pharmaceutical manufacturing industry achieved an operating income of 223 million yuan, accounting for 45.05% from 36.63% in the same period of last year, and its gross profit margin also increased by 6.7 1 percentage point to 59.70% year-on-year, much higher than the gross profit margin of pharmaceutical circulation business 13.52%. At present, the company produces a wide range of drugs, with more than 300 drug approval numbers (including pharmaceutical excipients and packaging materials) approved by National Medical Products Administration, covering anti-infection, cardiovascular and cerebrovascular diseases, respiratory diseases, digestive diseases, skin diseases, gynecological diseases and other fields. Among them, more than 100 products, such as Xiaofeifei granules, erythromycin enteric-coated capsules and Xuesaitong injection, entered the national essential drugs list, and more than 140 varieties were included in the national medical insurance list. Shen Yan Jianwei Capsule and Dizhen Granule are exclusive varieties of our company.